Aethlon Medical Inc (AEMD)

[My 2 Cents]

Aethlon Medical Inc. has added a news release to its Investor Relations website.

Title: Aethlon Medical Confirms Hemopurifier(R) Is a Treatment Candidate Against Swine Flu Virus
Date: 4/30/2009 7:15:00 AM

For a complete listing of our news releases, please click here

SAN DIEGO, April 30, 2009 /PRNewswire-FirstCall via COMTEX/ -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD) confirmed today that the Aethlon Hemopurifier(R) is a candidate to treat the H1N1 Swine flu virus. The Hemopurifier(R) is a first-in-class medical technology that assists the immune response in combating infectious disease through the selective adsorption of circulating viruses and immunosuppressive proteins. In the case of pandemic influenza, the Hemopurifier(R) has previously proven effective in capturing the reconstructed Spanish flu of 1918 virus (1918rv), the H5N1 avian influenza virus (Bird Flu), and would likely capture H1N1 swine flu as the technology selectively captures influenza viruses by hemagglutinin (HA) and neuraminidase (NA) glycoproteins that coat the virus, even when influenza mutates to be resistant against drug and vaccine therapies. As an example, H5N1 bird flu virus was documented to be resistant against Tamiflu, the globally stockpiled antiviral treatment for influenza.
(Photo: http://www.newscom.com/cgi-bin/prnh/20090325/LA88762-a)

(Logo: http://www.newscom.com/cgi-bin/prnh/20090325/LA88762LOGO-b)

"It is important that our shareholders understand we are fully cognizant of the potential opportunity associated with the emerging swine flu pandemic," stated Aethlon Chairman and CEO, Jim Joyce. "However, until this viral threat demonstrates resistance against Tamiflu treatment stockpiles, we shall remain focused on progressing our clinical and commercialization efforts against well-established infectious disease targets," concluded Joyce. Since the beginning of 2009, the Hemopurifier(R) has been demonstrated safe and effective in reducing patient viral load in both Hepatitis-C Virus (HCV) and Human Immunodeficiency Virus (HIV) infections. As a result, Aethlon believes the Hemopurifier(R) is the first therapeutic candidate to demonstrate viral reduction benefit against two different viral species in human studies. Such data further reinforces the position of the Hemopurifier(R) as a leading broad-spectrum countermeasure against drug and vaccine resistant viruses. Should H1N1 Swine Flu evolve to be highly virulent and resistant to treatment stockpiles, the Hemopurifier(R) is positioned to become a first-line treatment countermeasure to strengthen the clinical benefit of both established and candidate drug treatments. A report that reviews the application of the Hemopurifier(R) as a broad-spectrum countermeasure against bioterror and pandemic threats, including influenza, is available to be accessed online at www.aethlonmedical.com/pdfs/BroadSpectrumTreament120308.pdf